Opiant Pharmaceuticals, Inc.
OPNT · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Market Cap | $150 | $34 | $58 | $43 |
| - Cash | $38 | $48 | $31 | $25 |
| + Debt | $17 | $19 | $1 | $0 |
| Enterprise Value | $129 | $5 | $28 | $19 |
| Revenue | $41 | $27 | $38 | $14 |
| % Growth | 48.6% | -28.3% | 183% | – |
| Gross Profit | $32 | $21 | $31 | $12 |
| % Margin | 77.7% | 77.4% | 79.8% | 89% |
| EBITDA | $6 | -$2 | $11 | -$21 |
| % Margin | 14.3% | -5.6% | 29.2% | -156.4% |
| Net Income | $3 | -$2 | $12 | -$21 |
| % Margin | 7.4% | -6.8% | 30.3% | -156.8% |
| EPS Diluted | 0.51 | -0.44 | 2.17 | -7.1 |
| % Growth | 215.9% | -120.3% | 130.6% | – |
| Operating Cash Flow | $2 | -$2 | $4 | -$1 |
| Capital Expenditures | $0 | -$0 | -$0 | $0 |
| Free Cash Flow | $2 | -$2 | $4 | -$1 |